Colorectal Cancer Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Colorectal Cancer market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics

[Nevada, United States] - DelveInsight's "Colorectal Cancer Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Colorectal Cancer, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Colorectal Cancer Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Colorectal Cancer Market Report:
• The Colorectal Cancer market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Pfizer announced that the purpose of their study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer
• In October, 2024: Novartis announces that the purpose of their study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC.
• In October, 2024: Merck Sharp & Dohme LLC announced that in their study the participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma.
• In October, 2024: Seagen Inc. announced that a study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer.
• In October, 2024: BeiGene announced that their study will evaluate the safety, and tolerability of neo-adjuvant treatment with tislelizumab in participants with early-stage (Stage II-III) Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal cancer.
• In October, 2024: Amgen announced that their study will compare progression free survival (PFS) in treatment-naïve Participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
• In the US there were 116,000 cases of early stage CRC and 35,00 cases of advantage stage CRC in 2022.
• Among the EU4 countries, the highest number of incident cases of CRC were observed in Germany in 2022, while Spain accounted for the lowest number of incident cases of CRC.
• In Japan, the highest number of incident cases of CRC by age were observed in the 65─84 age group, followed by 45-64 years.
• Key Colorectal Cancer Companies are as follows: Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics
• Key Colorectal Cancer Therapies are as follow: Encorafenib, Cetuximab, Pembrolizumab, NIS793, Bevacizumab, mFOLFOX6 FOLFIRI, tucatinib trastuzumab, bevacizumab, Tislelizumab, FOLFIR, Sotorasib, Cetuximab, JX-594, oxaliplatin, levofolinate calcium, levofolinate calcium, Arfolitixorin, Leucovorin, QL1706, VELCADE, DS-8201a, SGM-101, GRT-C901, GRT-R902
• Launching multiple stage Colorectal Cancer pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Colorectal Cancer market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Colorectal Cancer Overview:
Colorectal cancer (CRC) is the third most common type of cancer, with metastasis being the major cause of death in the majority of patients. CRC that spreads, or metastasizes, to the lungs, liver, or any other organ is called metastatic colorectal cancer (mCRC). The major sites of tumor localization in CRC are the right colon, transverse, left colon, rectosigmoid.

Colorectal Cancer Epidemiology Segmentation:
The Colorectal Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Colorectal Cancer Incident Cases
• Colorectal Cancer Age-specific Incidence
• Colorectal Cancer Gender-specific Incidence
• Colorectal Cancer Mutation-specific Distribution

For more information about Colorectal Cancer companies working in the treatment market, visit https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Colorectal Cancer Market Insights
The global colorectal cancer market has witnessed notable growth over the past few years due to an increasing incidence of the disease, advancements in treatment, and improved early diagnosis. Factors like changing lifestyles, an aging population, and high consumption of processed foods contribute to the rising incidence. The market is projected to continue expanding due to ongoing research and development (R&D) and the introduction of novel therapies.

Colorectal Cancer Drugs Uptake
• Drugs like 5-fluorouracil (5-FU), oxaliplatin, and irinotecan are standard components of chemotherapy regimens. Capecitabine and Leucovorin are often used in combination to enhance effectiveness.
• Monoclonal antibodies like cetuximab and panitumumab target EGFR (epidermal growth factor receptor), while bevacizumab targets VEGF (vascular endothelial growth factor), inhibiting tumor growth by blocking the blood supply.
• Immune checkpoint inhibitors, particularly PD-1 inhibitors such as nivolumab and pembrolizumab, have shown efficacy in treating microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer. These therapies are often reserved for patients with metastatic disease.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Colorectal Cancer Therapies and Key Companies:
• Encorafenib, Cetuximab, Pembrolizumab: Pfizer
• NIS793, Bevacizumab: Novartis
• mFOLFOX6 FOLFIRI: Merck Sharp & Dohme LLC
• tucatinib trastuzumab, bevacizumab: Seagen Inc.
• Tislelizumab: BeiGene
• FOLFIRI, Sotorasib: Amgen
• Cetuximab: Eli Lilly and Company
• JX-594: Biotherapeutics
• oxaliplatin, levofolinate calcium, levofolinate calcium: Takeda
• Arfolitixorin, Leucovorin: Isofol Medical AB
• QL1706: Qilu Pharmaceutical Co., Ltd.
• VELCADE: Millennium Pharmaceuticals, Inc.
• DS-8201a: Daiichi Sankyo Co., Ltd.
• SGM-101: Surgimab
• GRT-C901, GRT-R902: Gritstone bio, Inc.

Colorectal Cancer Epidemiology:
Colorectal cancer is the third most diagnosed cancer globally, with approximately 1.9 million new cases reported annually. It is also the second leading cause of cancer-related deaths, accounting for about 935,000 deaths in 2020. The incidence varies significantly by region, with higher rates in developed countries, especially in Europe, North America, and Australia. However, the burden of CRC is also increasing in some low- and middle-income countries due to changes in dietary patterns and a rise in risk factors such as obesity, smoking, and a sedentary lifestyle.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Colorectal Cancer Market Drivers:
• Rising Global Incidence of Colorectal Cancer
• Improved Screening and Early Detection
• Development of Targeted Therapies and Immunotherapy
• R&D and Innovative Therapies in the Pipeline

Colorectal Cancer Market Barriers:
• Rising Global Incidence of Colorectal Cancer
• Advances in Diagnostic Technologies and Early Detection
• Development of Targeted Therapies and Immunotherapy
• Introduction of Novel Therapies and Expanding Treatment Options

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Colorectal Cancer Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Colorectal Cancer Companies: Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics
• Key Colorectal Cancer Therapies: Encorafenib, Cetuximab, Pembrolizumab, NIS793, Bevacizumab, mFOLFOX6 FOLFIRI, tucatinib trastuzumab, bevacizumab, Tislelizumab, FOLFIR, Sotorasib, Cetuximab, JX-594, oxaliplatin, levofolinate calcium, levofolinate calcium, Arfolitixorin, Leucovorin, QL1706, VELCADE, DS-8201a, SGM-101, GRT-C901, GRT-R902
• Colorectal Cancer Therapeutic Assessment: Current marketed and emerging therapies
• Colorectal Cancer Market Dynamics: Colorectal Cancer Market drivers and Colorectal Cancer barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Colorectal Cancer Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Colorectal Cancer market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Executive Summary of Colorectal Cancer (CRC)
4 Key Events
5 CRC Epidemiology and Market Forecast Methodology
6 CRC Market Overview at a Glance
7 Disease Background and Overview: CRC
8 Treatment and Management
9 Epidemiology and Patient Population of CRC in the 7MM
10 Patient Journey
11 Key Endpoints in CRC
12 Marketed Therapies
13 Emerging Therapies
14 CRC: Seven Major Market Analysis
15 Unmet Needs
16 SWOT Analysis
17 KOL Views
18 Market Access and Reimbursement
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.